Aarey Drugs Pharmaceuticals Ltd vs Bharat Immunological Biological Corporation Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Aarey Drugs & Pharmaceuticals Ltd is ₹ 88.45 as of 18 May 15:30 . The P/E Ratio of Aarey Drugs & Pharmaceuticals Ltd changed from 8.3 on March 2021 to 23.9 on March 2025 . This represents a CAGR of 23.56% over 5 yearsThe P/E Ratio of Bharat Immunological & Biological Corporation Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Aarey Drugs & Pharmaceuticals Ltd changed from ₹ 54.25 crore on March 2021 to ₹ 95.58 crore on March 2025 . This represents a CAGR of 11.99% over 5 yearsThe Market Cap of Bharat Immunological & Biological Corporation Ltd changed from ₹ 196.47 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of -100.00% over 5 years The revenue of Aarey Drugs & Pharmaceuticals Ltd for the Dec '25 is ₹ 100.61 crore as compare to the Sep '25 revenue of ₹ 84.95 crore. This represent the growth of 18.43% The revenue of Bharat Immunological & Biological Corporation Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Aarey Drugs & Pharmaceuticals Ltd for the Dec '25 is ₹ 2.67 crore as compare to the Sep '25 ebitda of ₹ 3.44 crore. This represent the decline of -22.38% The ebitda of Bharat Immunological & Biological Corporation Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Aarey Drugs & Pharmaceuticals Ltd changed from ₹ 1.24 crore to ₹ 0.57 crore over 7 quarters. This represents a CAGR of -35.86% The net profit of Bharat Immunological & Biological Corporation Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Aarey Drugs & Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Bharat Immunological & Biological Corporation Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Aarey Drugs & Pharmaceuticals Ltd

Aarey Drugs & Pharmaceuticals Limited was originally incorporated on May 15, 1990 as a private limited company in Mumbai with the name Niharika Textiles & Chemicals Private Limited.
The company was originally promoted by Prakash Mandhana, Kavita Mandhana and Neeta Mandhana.
In March, 1993, the Aarey Group of companies belonging to Ghatalia family took over the Company and it was converted into public limited company.
Also, the name of the company was changed from Niharika Textiles & Chemicals Private Limited to Aarey Drugs & Pharmaceuticals Limited. The Company is one of the manufacturer and suppliers of pharmaceutical raw materials, Chemicals, Pharmaceuticals ingredients, API's Drugs, Food Colours and Flavours.
The company is engaged in the business of manufacturing, selling of drugs & pharmaceutical products and is governed by a number of central and state legislations that regulate the business.

About Bharat Immunological & Biological Corporation Ltd

The Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL) is a Central Public Sector Unit, under the Department of Biotechnology, Ministry of Science and Technology.
BIBCOL was incorporated in 1989.
The Company is engaged in the manufacture of Oral Polio Vaccine (OPV) , Zinc Tablets and Diarehha management Kit and BIB Sweet Tablets. The company's manufacturing unit is located in Bulandshahr Dist., Uttar Pradesh.
BIBCL installed a plant of 100 mln units.
Commercial production of the OPV started from Jan'96. The company has received firm orders for supply of OPV from the Ministry of Health and Family Welfare, Government of India, for use in the national immunisation programme.

FAQs for the comparison of Aarey Drugs & Pharmaceuticals Ltd and Bharat Immunological & Biological Corporation Ltd

Which company has a larger market capitalization, Aarey Drugs & Pharmaceuticals Ltd or Bharat Immunological & Biological Corporation Ltd?

Market cap of Aarey Drugs & Pharmaceuticals Ltd is 250 Cr while Market cap of Bharat Immunological & Biological Corporation Ltd is 75 Cr

What are the key factors driving the stock performance of Aarey Drugs & Pharmaceuticals Ltd and Bharat Immunological & Biological Corporation Ltd?

The stock performance of Aarey Drugs & Pharmaceuticals Ltd and Bharat Immunological & Biological Corporation Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Aarey Drugs & Pharmaceuticals Ltd and Bharat Immunological & Biological Corporation Ltd?

As of May 18, 2026, the Aarey Drugs & Pharmaceuticals Ltd stock price is INR ₹88.45. On the other hand, Bharat Immunological & Biological Corporation Ltd stock price is INR ₹17.47.

How do dividend payouts of Aarey Drugs & Pharmaceuticals Ltd and Bharat Immunological & Biological Corporation Ltd compare?

To compare the dividend payouts of Aarey Drugs & Pharmaceuticals Ltd and Bharat Immunological & Biological Corporation Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.